Leaflet RYBREVANT 3520mg solution for injection

Indicated for: non-small cell lung cancer

Route of administration: injectable

Substance: amivantamab (monoclonal antibody)

ATC: L01FX18 (Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates)

Amivantamab is a monoclonal antibody used in the treatment of non-small cell lung cancer (NSCLC) with mutations in the EGFR (epidermal growth factor receptor) gene. It works by binding to EGFR and MET receptors, thereby inhibiting cellular signaling that promotes cancer cell growth and survival.

Amivantamab is administered intravenously, typically once a week during the initial weeks of treatment, followed by less frequent administrations as per the protocol established by the physician. The treatment is particularly indicated for patients with EGFR exon 20 mutations, which are resistant to other targeted therapies.

Common side effects include infusion-related reactions, skin rashes, diarrhea, nausea, and fatigue. In rare cases, severe reactions such as pneumonitis or liver toxicity may occur.

Patients receiving amivantamab should be closely monitored for adverse reactions and treatment efficacy. It is essential that the treatment is administered under the supervision of an oncologist experienced in targeted therapies. Amivantamab represents a promising option for patients with advanced NSCLC, offering a chance to control the disease in cases with specific genetic mutations.